


 10053
copy

PCT

 WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C07D 239/94, A61K 31/505, C07D 239/88, 239/93, 413/12, A61K 31/535, C07D 403/12, 401/12, 417/12, A61K 31/54	A1	(11) International Publication Number: WO 97/30035 (43) International Publication Date: 21 August 1997 (21.08.97)
(21) International Application Number: PCT/GB97/00365 (22) International Filing Date: 10 February 1997 (10.02.97) (30) Priority Data: ✓ 96400293.5 ✓ 13 February 1996 (13.02.96) EP (34) Countries for which the regional or international application was filed: FR et al. 96401756.0 8 August 1996 (08.08.96) EP (34) Countries for which the regional or international application was filed: FR et al. 96402764.3 17 December 1996 (17.12.96) EP (34) Countries for which the regional or international application was filed: FR et al. (71) Applicants (for all designated States except US): ZENECA LIMITED [GB/GB]; 15 Stanhope Gate, London W1Y 6LN (GB). ZENECA PHARMA S.A. [FR/FR]; "Le Galien", rue des Chauffours, Boite postale 27, F-95022 Cergy Cédex (FR). (72) Inventors; and (75) Inventors/Applicants (for US only): THOMAS, Andrew Peter [GB/GB]; Alderley Park, Macclesfield, Cheshire SK10	(74) Agent: MACK, John, Richard; Zeneca Pharmaceuticals, Intel- lectual Property Dept., Mereside, Alderley Park, Maccles- field, Cheshire SK10 4TG (GB). (81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.	
(54) Title: QUINAZOLINE DERIVATIVES AS VEGF INHIBITORS		
(57) Abstract The invention relates to quinazoline derivatives of formula (I) [wherein: Z represents -O-, -NH- or -S-; m is an integer from 1 to 5; R¹ represents hydrogen, hydroxy, halogeno, nitro, trifluoromethyl, cyano, C₁-alkyl, C₁-alkoxy, C₁-alkylthio, or -NR⁵R⁶ (wherein R⁵ and R⁶, which may be the same or different, each represents hydrogen or C₁-alkyl); R² represents hydrogen, hydroxy, halogeno, methoxy, amino or nitro; R³ represents hydroxy, halogeno, C₁-alkyl, C₁-alkoxy, C₁-alkanoyloxy, trifluoromethyl, cyano, amino or nitro; X¹ represents -O-, -CH₂-, -S-, -SO-, -SO₂-, -NR⁷-, -NR⁸CO-, -CONR⁹-, -SO₂NR¹⁰-, or -NR¹¹SO₂-, (wherein R⁷, R⁸, R⁹, R¹⁰ and R¹¹ each represents hydrogen, C₁-alkyl or C₁-alkoxyC₂-alkyl); R⁴ represents a group which is alkenyl, alkynyl or optionally substituted alkyl, which alkyl group may contain a heteroatom linking group, which alkenyl, alkynyl or alkyl group may carry a terminal optionally substituted 5 or 6 membered saturated carbocyclic or heterocyclic group] and salts thereof; processes for their preparation, pharmaceutical compositions containing a compound of formula (I) or a pharmaceutically acceptable salt thereof as active ingredient. The compounds of formula (I) and the pharmaceutically acceptable salts thereof inhibit the effects of VEGF, a property of value in the treatment of a number of disease states including cancer and rheumatoid arthritis. (I)		